Chloroquine efficacy for Plasmodium vivax in Myanmar in populations with high genetic diversity and moderate parasite gene flow.
<p><strong>BACKGROUND:</strong><em>Plasmodium vivax</em> malaria remains a major public health burden in Myanmar. Resistance to chloroquine (CQ), the first-line treatment for <em>P. vivax</em>, has been reported in the country and has potential to undermine...
Hlavní autoři: | Htun, M, Mon, N, Aye, K, Hlaing, C, Kyaw, M, Handayuni, I, Trimarsanto, H, Bustos, D, Ringwald, P, Price, R, Auburn, S, Thriemer, K |
---|---|
Médium: | Journal article |
Jazyk: | English |
Vydáno: |
BioMed Central
2017
|
Podobné jednotky
-
Where chloroquine still works: the genetic make-up and susceptibility of Plasmodium vivax to chloroquine plus primaquine in Bhutan
Autor: Wangchuk, S, a další
Vydáno: (2016) -
Chloroquine efficacy for Plasmodium vivax malaria treatment in southern Ethiopia
Autor: Getachew, S, a další
Vydáno: (2015) -
Plasmodium vivax resistance to chloroquine in Dawei, southern Myanmar.
Autor: Guthmann, J, a další
Vydáno: (2008) -
Plasmodium vivax trophozoites insensitive to chloroquine.
Autor: Sharrock, W, a další
Vydáno: (2008) -
Therapeutic Responses of Plasmodium vivax Malaria to Chloroquine and Primaquine Treatment in Northeastern Myanmar.
Autor: Yuan, L, a další
Vydáno: (2014)